XTL Biotechnologies

XTL Biotechnologies is a clinical-stage biopharmaceutical company headquartered in Israel, specializing in the acquisition and development of therapeutic candidates for unmet medical needs. The company's primary focus is on autoimmune diseases and oncology, with a lead program centered on hCDR1 (Edratide), a synthetic peptide for the treatment of Systemic Lupus Erythematosus (SLE). XTL is also advancing a program using recombinant human erythropoietin (rHuEPO) to treat multiple myeloma, aiming to extend survival and remission in patients. The company's business model involves licensing promising assets from academic institutions, such as the Weizmann Institute of Science, and progressing them through clinical trials. XTL is publicly traded on both the NASDAQ and the Tel Aviv Stock Exchange under the symbol XTLB. Recently, the company has signaled a strategic expansion into the data and artificial intelligence sectors through corporate acquisitions.